Physicochemical Properties
|
Molecular weight (g/mol) |
407.92 |
391.92 |
No. of heavy atoms |
27 |
26 |
No. of aromatic heavy atoms |
10 |
10 |
Fraction Csp3
|
0.39 |
0.39 |
No. of rotatable bonds |
8 |
7 |
No. of H-bond acceptors |
5 |
4 |
No. of H-bond donors |
2 |
2 |
Molar refractivity |
114.72 |
113.20 |
TPSA (Å2) |
103.10 |
93.87 |
Lipophilicity
|
Log Po/w (iLOGP) |
3.65 |
3.21 |
Log Po/w (XLOGP3) |
2.47 |
2.86 |
Log Po/w (WLOGP) |
1.65 |
1.95 |
Log Po/w (MLOGP) |
0.97 |
1.50 |
Log Po/w (SILICOS-IT) |
3.96 |
4.41 |
Consensus Log Po/w
|
2.54 |
2.79 |
Water Solubility
|
Log S (ESOL) |
−3.67 |
−3.89 |
Solubility (mg/mL; mol/L) |
8.70 × 10−2; 2.13 × 10−4
|
5.00 × 10−2; 1.28 × 10−4
|
Class |
Soluble |
Soluble |
Log S (ALi) |
−4.28 |
−4.49 |
Solubility(mg/ml; mol/l) |
2.14 × 10−2; 5.26 × 10−5
|
1.27 × 10−2; 3.23 × 10−5
|
Class |
Moderately soluble |
Moderately soluble |
Log S (SILICOS-IT) |
−5.70 |
−5.98 |
Solubility (mg/ml; mol/l) |
8.06 × 10−4; 1.98 × 10−6
|
4.13 × 10−4; 1.05 × 10−6
|
Class |
Moderately soluble |
Moderately soluble |
Pharmacokinetics
|
GI absorption |
High |
High |
BBB permeant |
No |
No |
P-gp substrate |
Yes |
Yes |
CYP1A2 inhibitor |
Yes |
Yes |
CYP2C19 inhibitor |
Yes |
Yes |
CYP2C9 inhibitor |
Yes |
Yes |
CYP2D6 inhibitor |
No |
Yes |
CYP3A4 inhibitor |
Yes |
Yes |
Log Kp (skin permeation) (cm/s) |
−7.03 |
−6.66 |
Druglikeness
|
Lipinski |
Yes; 0 violation |
Yes; 0 violation |
Ghose |
Yes; 0 violation |
Yes; 0 violation |
Veber |
Yes; 0 violation |
Yes; 0 violation |
Egan |
Yes; 0 violation |
Yes; 0 violation |
Muegge |
Yes; 0 violation |
Yes; 0 violation |
Bioavailability score |
0.55 |
0.55 |
Medicinal Chemistry
|
PAINS |
0 alert |
0 alert |
Brenk |
3 alerts: 2-halo_pyridine, imine_1, thiocarbonyl_group |
3 alerts: 2-halo_pyridine, imine_1, thiocarbonyl_group |
Leadlikeness |
No; 2 Violations: MW > 350, Rotors > 7 |
No; 1 Violation MW > 350 |
Synthetic accessibility |
3.16 |
3.18 |